Ahmad Munir, MD
Interventional Cardiology · Flint, MINPI 1730145228
Payments from drug & device makers
Across 592 payments — averaging $333.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$163K
- Abbott$23K
- Inari Medical, Inc.$4K
- Abiomed$2K
- Amgen$699
- Pfizer$640
- plus $4K from 31 others
What the payments were for
- Speaking & faculty fees$151,00086%
- Travel & lodging$11,0496%
- Food & beverage$13,6078%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 266 | $162,617 |
| Abbott | 70 | $22,888 |
| Inari Medical, Inc. | 18 | $4,396 |
| Abiomed | 29 | $2,152 |
| Amgen | 24 | $699 |
| Pfizer | 20 | $640 |
| Novartis | 29 | $560 |
| Actelion Pharmaceuticals US, Inc. | 17 | $354 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $310 |
| Alnylam Pharmaceuticals Inc. | 12 | $309 |
| Edwards Lifesciences | 8 | $301 |
| Johnson & Johnson | 19 | $274 |
| Boston Scientific | 4 | $257 |
| E.r. Squibb & Sons, L.L.C. | 10 | $256 |
| Kestra Medical Technology Services, Inc. | 4 | $198 |
| AstraZeneca | 6 | $197 |
| Cardiva Medical, Inc. | 5 | $184 |
| Merck | 11 | $176 |
| Angiodynamics, Inc. | 2 | $150 |
| Boehringer Ingelheim | 2 | $87 |
| Teleflex LLC | 4 | $69 |
| Vital Connect, Inc | 2 | $58 |
| Heartflow, Inc. | 3 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $51 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $48 |
| Terumo Medical Corporation | 2 | $31 |
| Corcept Therapeutics | 1 | $27 |
| Amarin Pharma, Inc. | 2 | $26 |
| Cardiovascular Systems Inc. | 2 | $25 |
| Bayer | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Z-medica, LLC | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| Bardy Diagnostics, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$85,900
- COREVALVE EVOLUT R$73,369
- FLOWTRIEVER CATHETER, S$3,814
- CT THROMBECTOMY SYSTEM KIT$3,814
- Impella$1,253
- VYNDAQEL$290
- CARDIOMEMS$257
- Repatha$228
- SYMPLICITY G3$176
- AngioVac$131
- WATCHMAN Access System$126
- FARXIGA$125
- ONPATTRO$125
- SavvyWire$124
- Micra$109
- MitraClip System$104
- Assure WCD$103
How this compares
$197,561 in reported general payments places this provider in the 80th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $91,194 |
| BrilintaTicagrelor | 41 | $31,326 |
| XareltoRivaroxaban | 26 | $26,232 |
| Repatha SureclickEvolocumab | 13 | $14,178 |
| EntrestoSacubitril/Valsartan | 13 | $11,818 |
| ClopidogrelClopidogrel Bisulfate | 118 | $3,105 |
| Metoprolol Succinate | 117 | $1,757 |
| Atorvastatin Calcium | 89 | $1,343 |
| Rosuvastatin Calcium | 47 | $1,001 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $948 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 38 | $586 |
| Metoprolol Tartrate | 88 | $576 |
| Losartan Potassium | 63 | $561 |
| Potassium Chloride | 20 | $364 |
| Carvedilol | 16 | $312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $640 | $91,19466 claims |
| AstraZenecaBrilinta | $197 | $31,32641 claims |
| Johnson & JohnsonXarelto | $274 | $26,23226 claims |
| NovartisEntresto | $560 | $11,81813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Flint
- Ahmed BakhitFlint$61K
- Samir ElianFlint$32K
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.